Yao S, Ye Z, Wei Y, Jiang HY, Song B. Radiomics in hepatocellular carcinoma: A state-of-the-art review. World J Gastrointest Oncol 2021; 13(11): 1599-1615 [PMID: 34853638 DOI: 10.4251/wjgo.v13.i11.1599]
Corresponding Author of This Article
Bin Song, MD, PhD, Chief Doctor, Director, Professor, Department of Radiology, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, Sichuan Province, China. cjr.songbin@vip.163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Nov 15, 2021; 13(11): 1599-1615 Published online Nov 15, 2021. doi: 10.4251/wjgo.v13.i11.1599
Radiomics in hepatocellular carcinoma: A state-of-the-art review
Shan Yao, Zheng Ye, Yi Wei, Han-Yu Jiang, Bin Song
Shan Yao, Zheng Ye, Yi Wei, Han-Yu Jiang, Bin Song, Department of Radiology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Yao S and Song B designed the research; Yao S and Ye Z conducted literature search and analysis; Yao S wrote the paper; Yao S and Ye Z made critical revisions to the manuscript; Wei Y and Jiang HY provided material support; Song B provided funding for the article.
Supported byThe Science and Technology Support Program of Sichuan Province, No. 2021YFS0021 and No. 2021YFS0144; and the National Natural Science Foundation of China, No. 81771797 and No. 81971571.
Conflict-of-interest statement: All authors declare no potential conflict of interests related to this publication.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bin Song, MD, PhD, Chief Doctor, Director, Professor, Department of Radiology, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, Sichuan Province, China. cjr.songbin@vip.163.com
Received: February 22, 2021 Peer-review started: February 22, 2021 First decision: April 19, 2021 Revised: April 22, 2021 Accepted: August 20, 2021 Article in press: August 20, 2021 Published online: November 15, 2021 Processing time: 262 Days and 19.5 Hours
Abstract
Hepatocellular carcinoma (HCC) is the most common cancer and the second major contributor to cancer-related mortality. Radiomics, a burgeoning technology that can provide invisible high-dimensional quantitative and mineable data derived from routine-acquired images, has enormous potential for HCC management from diagnosis to prognosis as well as providing contributions to the rapidly developing deep learning methodology. This article aims to review the radiomics approach and its current state-of-the-art clinical application scenario in HCC. The limitations, challenges, and thoughts on future directions are also summarized.
Core Tip: Medical imaging plays an indispensable role in hepatocellular carcinoma (HCC) clinical settings. Conventional imaging methods, however, provide limited and insufficient information. Recent studies have shown that radiomics and deep learning enable comprehensive insightful data mining that has achieved favorable performance in the detection and classification, diagnosis and differentiation, staging and grading, aggressive behavior, treatment responses, prognosis, and survival rates of HCC. Nevertheless, the wide implementation of radiomics and deep learning in actual routine clinical practice requires sustainable validation and optimization.